H.C. Wainwright lowered the firm’s price target on Adaptimmune (ADAP) to $3.50 from $4 and keeps a Buy rating on the shares following the Q3 report.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter